G1 Therapeutics Inc (NASDAQ: GTHX) is 132.79% higher on its value in year-to-date trading and has touched a low of $1.08 and a high of $7.12 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GTHX stock was last observed hovering at around $7.09 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $7.10, the stock is 31.91% and 84.94% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.65 million and changing 0.14% at the moment leaves the stock 104.12% off its SMA200. GTHX registered 290.11% gain for a year compared to 6-month gain of 214.16%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 93.46% loss in the last 1 month and extending the period to 3 months gives it a 56.04%, and is 0.28% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 0.31% over the week and 5.44% over the month.
G1 Therapeutics Inc (GTHX) has around 100 employees, a market worth around $371.19M and $58.20M in sales. Fwd P/E is 67.09. Profit margin for the company is -76.93%. Distance from 52-week low is 557.41% and -0.28% from its 52-week high. The company has generated returns on investments over the last 12 months (-73.22%).
The EPS is expected to grow by 56.74% this year.
G1 Therapeutics Inc (GTHX) Top Institutional Holders
115.0 institutions hold shares in G1 Therapeutics Inc (GTHX), with institutional investors hold 49.66% of the company’s shares. The shares outstanding are 51.93M, and float is at 42.79M with Short Float at 13.48%. Institutions hold 44.24% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 2.08 million shares valued at $8.99 million. The investor’s holdings represent 4.0236 of the GTHX Shares outstanding. As of 2024-03-31, the second largest holder is SUSQUEHANNA INTERNATIONAL GROUP, LLP with 0.95 million shares valued at $4.11 million to account for 1.838 of the shares outstanding. The other top investors are RENAISSANCE TECHNOLOGIES LLC which holds 0.9 million shares representing 1.7468 and valued at over $3.9 million, while RAYMOND JAMES & ASSOCIATES holds 1.5519 of the shares totaling 0.8 million with a market value of $3.47 million.
G1 Therapeutics Inc (GTHX) Insider Activity
The most recent transaction is an insider sale by Perry Andrew, the company’s Chief Commercial Officer. SEC filings show that Perry Andrew sold 1,337 shares of the company’s common stock on Jul 05 ’24 at a price of $2.51 per share for a total of $3353.0. Following the sale, the insider now owns 0.11 million shares.
G1 Therapeutics Inc disclosed in a document filed with the SEC on Jul 05 ’24 that MURDOCK TERRY L (Chief Operating Officer) sold a total of 2,475 shares of the company’s common stock. The trade occurred on Jul 05 ’24 and was made at $2.51 per share for $6207.0. Following the transaction, the insider now directly holds 0.13 million shares of the GTHX stock.
Still, SEC filings show that on Jul 05 ’24, Malik Rajesh (Chief Medical Officer) disposed off 2,475 shares at an average price of $2.51 for $6207.0. The insider now directly holds 159,312 shares of G1 Therapeutics Inc (GTHX).
